BiotechTube
Home/Pipeline/Parkinson’s Disease Model

Parkinson’s Disease Model

Parkinson's Disease

ResearchActive

Key Facts

Indication
Parkinson's Disease
Phase
Research
Status
Active
Company
Neurix

About Neurix

Neurix is a private, Switzerland-based biotech company leveraging human iPSC technology to create advanced 3D in vitro models of the brain for preclinical research. Its core business is providing specialized research services and proprietary model systems, such as its BlastomaBrain™ glioblastoma model, to pharmaceutical and academic partners to improve the predictability of neuroscience drug discovery. The company is led by a team with strong scientific and business backgrounds and has been supported by European research funding. Neurix operates as a pre-revenue platform and services company, focusing on neurodegenerative diseases and neuro-oncology.

View full company profile

Therapeutic Areas

Neurodegenerative DiseasesNeuro-oncology

Other Parkinson's Disease Drugs

DrugCompanyPhase
NPT200-11Neuropore TherapiesPhase 1
NUZ-001Neurizon TherapeuticsPreclinical
VXX-301VaxxinityPreclinical
BAN2802BioArcticPhase 1
CNM-Au8ClenePhase 2
hpSC-Derived Neural/Dopaminergic CellsInternational Stem CellPreclinical/Early Clinical
SLS-004Seelos TherapeuticsPreclinical
SLS-007Seelos TherapeuticsPreclinical
Parkinson's Disease Portfolio (Platform-derived)WD PharmaceuticalNot Disclosed (Likely Preclinical/Early Clinical)
UX-DA001UniXellPhase 1
Parkinson's Disease ResearchProgenaBiomeResearch
A9 Dopaminergic Neuron TherapyTrailhead BiosystemsPre-clinical